Verseon
Verseon develops treatments for major human diseases using physics and AI-driven precision engineering, focusing on first-in-class drug candidates to change the standard of care.
Company History
Verseon develops treatments for a range of major human diseases using physics and AI-driven precision engineering. The company focuses on creating first-in-class drug candidates to change the standard of care for the diseases it addresses. It pioneers real-time explainable AI, which provides robust insights into how AI models reach decisions. The company has also received a US patent for a drug candidate (PROAC) that aims to significantly improve the standard of care for several hundred million cardiovascular patients.
Services
Verseon specializes in developing first-in-class drug candidates by leveraging AI-driven precision engineering and advancements in quantum physics. Their proprietary AI platform enables them to identify and develop effective drug candidates aimed at changing the standard of care for various major diseases. The company provides robust insights into AI decision-making through their real-time explainable AI technology, ensuring transparency and reliability in the drug development process.
Drug Development Pipeline
Verseon has a varied drug development pipeline with candidates in different stages, including clinical, IND-prep, preclinical, and optimization. For cardiovascular diseases, they are developing VE-1902 and VE-2851 to prevent heart attacks and strokes with lower bleeding risk, currently in the clinical stage. For diabetic vision loss, they have VE-4840 and VE-3539 in the IND-prep stage, aiming to eliminate the need for eye injections. For treating multidrug-resistant cancers, VE-4054 and VE-4932 are in the preclinical stage. In the optimization stage, VE-2843 and VE-1787 are being developed to prevent aggressive solid-tumor cancer metastasis. Additionally, VE-3771 and VE-5953, both in the preclinical stage, aim to restore immune response to CD73 positive cancers.
Technological Innovations
Verseon leads in utilizing proprietary explainable AI and breakthroughs in quantum physics to advance its drug discovery and development processes. Their real-time explainable AI technology is pivotal in providing clear and robust insights into AI decision-making. This technological innovation ensures that the AI models used in drug discovery are reliable and transparent, enhancing the efficacy and accuracy of developing first-in-class drug candidates poised to improve the standard of care for major diseases.